Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Summary not available.
Kymera Therapeutics (NASDAQ: KYMR) is set to report its first quarter 2023 financial results on May 4, 2023, with a conference call scheduled for 8:30 a.m. ET. The company, known for its innovative approach to targeted protein degradation, has outlined its participation in several upcoming investor conferences, including Stifel Virtual Targeted Oncology Days on April 25, 2023, BofA Securities Health Care Conference on May 10, 2023, and Piper Sandler Spring Biopharma Symposium on May 18, 2023. Kymera’s drug discovery engine focuses on targeting disease-causing proteins and aims to advance its therapeutic pipeline for various diseases, including immune-inflammatory diseases and hematologic malignancies.
Kymera Therapeutics (NASDAQ: KYMR), a biopharmaceutical company focused on targeted protein degradation, has announced upcoming investor events. The management team will participate in the Cowen 43rd Annual Health Care Conference in Boston, MA from March 6-8, 2023, with CEO Nello Mainolfi presenting a fireside chat on March 6 at 10:30 AM ET, alongside hosting 1x1 meetings. Additionally, the Jefferies Biotech on the Bay Summit in Miami, FL will take place on March 16-17, 2023, where the company will conduct 1x1 meetings only. A live webcast of the fireside chat will be available on their website.
Kymera Therapeutics (NASDAQ: KYMR) reported significant developments in its drug programs during its Q4 2022 results, highlighting continued progress in targeted protein degradation. The company plans to initiate Phase 2 trials for IRAK4 degrader KT-474, backed by a strong cash balance of approximately $560 million, ensuring funding through mid-2025. The KT-474 Phase 1 trials yielded positive results in treating hidradenitis suppurativa and atopic dermatitis. In addition, ongoing trials for KT-333 and KT-413 have shown promising early results. The company aims to launch the KT-253 Phase 1 trial in early 2023, further expanding its innovative pipeline.
Kymera Therapeutics (NASDAQ: KYMR) will announce its Q4 and full year 2022 financial results on February 23, 2023, followed by a conference call at 8:30 a.m. ET. The company focuses on targeted protein degradation to develop innovative therapies for challenging disease targets. Upcoming investor engagements include the Guggenheim Oncology Conference on February 8 and others through February 21. The company aims to advance therapies targeting IRAK4, IRAKIMiD, STAT3, and MDM2, with expectations to progress its clinical trials and maintain a solid financial runway into H2 2025.
X-Chem has expanded its collaboration with Kymera Therapeutics (NASDAQ: KYMR), now the primary provider of DNA-encoded library (DEL) screening services. The partnership covers 12 targets, granting Kymera exclusive rights to discovered compounds. This collaboration aims to enhance Kymera's efforts in developing innovative protein degraders, crucial for addressing challenging disease targets. Kymera's CEO praised X-Chem’s libraries for their quality and scientific rigor, reflecting a commitment to revolutionizing medicine through targeted protein degradation.
Kymera Therapeutics (NASDAQ: KYMR) announced its 2023 goals after a pivotal 2022, where its lead program KT-474 demonstrated an encouraging safety profile in inflammatory diseases. The company ended 2022 with approximately $560 million in cash, expected to fund operations into 2025. Major objectives for 2023 include initiating Phase 2 trials for KT-474, demonstrating clinical activity in oncology programs KT-413 and KT-333, and commencing Phase 1 trials for KT-253. The company aims to leverage its discovery platform to develop novel therapeutics targeting disease-causing proteins.
Kymera Therapeutics (NASDAQ: KYMR) appointed Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary. Chiniara brings extensive legal experience from biopharmaceutical companies and will oversee Kymera’s legal and governance functions. CEO Nello Mainolfi highlighted her leadership in advancing the company as it aims to become a fully integrated global biopharmaceutical entity. Chiniara previously served at Alexion Pharmaceuticals and Alere, enhancing legal operations and corporate social responsibility initiatives.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 9:00 AM PST. CEO Nello Mainolfi will discuss the company's advancements and goals for 2023. Kymera is pioneering targeted protein degradation, developing innovative small molecule therapies to address previously inaccessible disease targets. Its pipeline includes candidates targeting IRAK4, IRAKIMiD, STAT3, and MDM2, aimed at treating various immune-inflammatory diseases and cancers. A live webcast will be available on their website.
Kymera Therapeutics (NASDAQ: KYMR) has reported promising results from its KT-474 Phase 1 clinical trial for hidradenitis suppurativa (HS) and atopic dermatitis (AD). The study demonstrated significant IRAK4 knockdown in blood and skin lesions, alongside a favorable safety profile. Notably, after four weeks of dosing, a majority of patients showed substantial clinical improvement. Following these results, Sanofi has committed to advancing KT-474 into Phase 2 trials. The company is also progressing with its oncology programs, including KT-413, KT-333, and KT-253.